Table 2.
Daily glucocorticoid dose use at the time of relapse for GCA (N = 24) and PMR (N = 21) patients.
| GC dose (mg/day) at relapse | GCA relapses (%) | PMR relapses (%) |
|---|---|---|
| 0 | 6 (21) | 5 (25) |
| 1–5 | 10 (35) | 3 (15) |
| 6–10 | 7 (24) | 6 (30) |
| 11–20 | 6 (21) | 5 (25) |
| >20 | 0 | 1 (5) |
| Total | 29 | 20 |
In patients that were followed for 2 years, we registered the daily GC dose at which they relapsed. Relapses were defined by clinical signs and symptoms only. GC, glucocorticoid; GCA, giant cell arteritis; PMR, polymyalgia rheumatica.